MX2010003881A - El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano. - Google Patents

El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.

Info

Publication number
MX2010003881A
MX2010003881A MX2010003881A MX2010003881A MX2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A
Authority
MX
Mexico
Prior art keywords
tpora
receptor agonist
myeloid leukemia
human myeloid
thrombopoietin receptor
Prior art date
Application number
MX2010003881A
Other languages
English (en)
Inventor
Connie L Erickson-Miller
Alan M Gewirtz
Anna Kolata
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2010003881A publication Critical patent/MX2010003881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee métodos para inhibir el crecimiento y proliferación de células de leucemia mieloide humana al administrar un agonista del receptor de trombopoyetina (TpoRA), un derivado o una variante del mismo a un individuo que padece MLA.
MX2010003881A 2007-10-09 2008-10-08 El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano. MX2010003881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99812607P 2007-10-09 2007-10-09
PCT/US2008/079205 WO2009048953A1 (en) 2007-10-09 2008-10-08 Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells

Publications (1)

Publication Number Publication Date
MX2010003881A true MX2010003881A (es) 2010-07-28

Family

ID=40549531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003881A MX2010003881A (es) 2007-10-09 2008-10-08 El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.

Country Status (12)

Country Link
US (1) US8530508B2 (es)
EP (1) EP2211855A4 (es)
JP (1) JP5393691B2 (es)
KR (1) KR101530402B1 (es)
CN (1) CN101888841B (es)
AU (1) AU2008310894B2 (es)
BR (1) BRPI0818346A2 (es)
CA (1) CA2709224C (es)
EA (1) EA022915B1 (es)
MX (1) MX2010003881A (es)
WO (1) WO2009048953A1 (es)
ZA (1) ZA201002499B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
WO2016205784A1 (en) * 2015-06-19 2016-12-22 The Scripps Research Institute Methods and compositions for producing activated natural killer cells and related uses
US20240010736A1 (en) * 2020-11-24 2024-01-11 Daegu Gyeongbuk Institute Of Science And Technology Novel anti-c-mpl antibody and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
JP2001521896A (ja) 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
EP2138179A1 (en) * 1999-03-29 2009-12-30 Shire Canada Inc. Use of cytidine derivatives for the treatment of leukaemia
CN1376150A (zh) 1999-07-26 2002-10-23 盐野义制药株式会社 具有血栓形成素受体拮抗作用的药物组合物
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
ATE292640T1 (de) 2000-05-31 2005-04-15 Genzyme Corp Therapeutische verbindungen gegen eierstockkrebs
WO2002015926A1 (fr) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes
ATE290882T1 (de) 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP1354880A4 (en) 2001-01-26 2004-08-25 Shionogi & Co HALOGEN COMPOUNDS HAVING AGONISM TOWARDS THROMBOPOIETIN RECEPTOR
WO2002059099A1 (fr) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
US20040077697A1 (en) 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
US20030171306A1 (en) * 2001-06-04 2003-09-11 Davis Stephen Thomas Cancer treatment method
CN1319967C (zh) 2002-01-18 2007-06-06 安斯泰来制药有限公司 2－酰基氨基噻唑衍生物或其盐
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US20070105824A1 (en) 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
EP1805155B1 (en) 2004-10-25 2010-11-03 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
EP1942906A2 (en) 2005-10-13 2008-07-16 SmithKline Beecham Corporation Methods for the preservation of platelet efficacy during storage
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2008011666A (es) 2006-03-15 2008-10-17 Ligand Pharm Inc Sintesis de compuestos que modulan la actividad de la trombopoyetina.
US20090304634A1 (en) 2006-12-12 2009-12-10 Smithkline Beecham Corporation Novel Combinations
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
WO2009151862A1 (en) 2008-05-15 2009-12-17 Smithkline Beecham Corporation Method of treatment
US20120149749A1 (en) 2008-10-16 2012-06-14 Michael Arning Method of treating thrombocytopenia

Also Published As

Publication number Publication date
AU2008310894B2 (en) 2012-07-26
AU2008310894A1 (en) 2009-04-16
WO2009048953A1 (en) 2009-04-16
CA2709224C (en) 2015-06-23
CN101888841A (zh) 2010-11-17
EP2211855A4 (en) 2011-12-07
BRPI0818346A2 (pt) 2015-04-07
KR20100106952A (ko) 2010-10-04
CN101888841B (zh) 2012-09-26
EA022915B1 (ru) 2016-03-31
US8530508B2 (en) 2013-09-10
US20100298398A1 (en) 2010-11-25
KR101530402B1 (ko) 2015-06-19
JP2011500580A (ja) 2011-01-06
JP5393691B2 (ja) 2014-01-22
ZA201002499B (en) 2010-12-29
EP2211855A1 (en) 2010-08-04
CA2709224A1 (en) 2009-04-16
EA201070441A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
MX2010002285A (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas.
TW200700009A (en) Active compound combinations having insecticidal and acaricidal properties
WO2010056378A3 (en) Extracellular matrix compositions for the treatment of cancer
MY172151A (en) Certain chemical entities, compositions and methods
TN2011000222A1 (en) Melanocortin receptor agonists
NZ622566A (en) Chromobacterium bioactive compositions and metabolites
MX2007011048A (es) Composiciones estables de peroxido organico.
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX2010008359A (es) Variantes de alfa-amilasa ts23 con propiedades alteradas.
MX2009006304A (es) Nuevos compuestos de oxadiazol.
MX2009010071A (es) Derivados de aril isoxazolina insecticidas.
MY153915A (en) Organic compounds
MX2011013705A (es) Procedimiento para mejorar el crecimiento de las plantas y/o la emergencia precoz de los cultivos.
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
IN2013DN02552A (es)
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
MX2010002656A (es) Formulaciones y dispositivos para suministro de compuestos a artropodos y microorganismos dentro de artropodos.
WO2009129208A3 (en) Compositions and methods of inducing endoplasmic reticulum stress reponse
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
MX2012013478A (es) Composicion para evitar perdida del cabello o estimular crecimiento del cabello.
MX2010003881A (es) El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments

Legal Events

Date Code Title Description
FG Grant or registration